Document:

<PAGE>

                              CONSULTING AGREEMENT

         This Agreement is effective as of the 17th day of December, 1998, by
and between Steroidogenesis Inhibitors International, a Nevada corporation (the
"Company"), and The Augustine Equity Fund, a Canadian corporation (the
"Consultant").

         WHEREAS, the Company is a publicly held company; and

         WHEREAS, the Company desires to retain the Consultant to provide
certain services for the Company, as more particularly described in this
Agreement.

         NOW, THEREFORE, in consideration of the mutual covenants and promises
contained herein, the receipt and sufficiency of which is hereby acknowledged,
the parties hereby agree as follows:

         1. Duties and Involvement.

                  a. The Company hereby engages Consultant to provide
recommendations concerning the Company's capital structure and methods of
obtaining capital on a debt or equity basis; recommend and implement a plan to
increase investor and broker-dealer awareness of the Company; to review,
recommend, and assist in the implementation of broker and investor relations
programs; and assist in the preparation for and format of due diligence meetings
with brokers.

                  b. Consultant acknowledges that neither it nor any of its
employees or affiliates is an officer, director, or agent of the Company, that
in rendering advice or recommendations to the Company it is not and will not be
responsible for any management decisions on behalf of the Company, and that it
is not authorized or empowered to commit the Company to any recommendation or
course of action. The Company represents that Consultant does not have, through
stock ownership or otherwise, the power to control the Company nor to exercise
any dominating influence over its management.

         2. Term. This Agreement shall continue for three (3) years from the
date first above written.

         3. Compensation.

                  a. As consideration for the services to be provided by
Consultant to the Company, the Company hereby issues and sells to the Consultant
or its designees One

                                        1

<PAGE>

Hundred Thousand (100,000) shares of the Company's common stock, par value
$.0001, in accordance with and pursuant to the exemption from registration
available under Regulation D, Rule 504, promulgated under Section 3(b) of the
Securities Act of 1933, as amended.

                  b. The compensation payable to Consultant under Section 3.a.
hereof shall be Consultant's sole compensation and payment for the services to
be rendered by Consultant pursuant to this Agreement, and Consultant shall be
responsible for, and shall itself pay, the out-of-pocket expenses of Consultant
related to the performance of Consultant's services hereunder.

         4. Services Not Exclusive. Consultant shall devote such of its time and
effort as may be necessary to the discharge of its duties hereunder. The Company
acknowledges that Consultant is engaged in other business activities and that it
will continue such activities during the term of this Agreement. Consultant
shall not be restricted from engaging in other business activities during the
term of this Agreement.

         5. Confidentiality. Consultant acknowledges that it will have access to
confidential information regarding the Company and its business. Consultant
agrees that it will not, during or subsequent to the term of this Agreement,
divulge, furnish, or make accessible to any person (other than with the written
permission of the Company) any knowledge or information or plans of the Company
with respect to the Company or its business, including, but not limited to, the
products of the Company, whether in the concept or development stage or being
marketed by the Company on the effective date of this Agreement or during the
term hereof.

         6. Investment Representation

            Access to Information. The Company represents and warrants that it
has provided Consultant access to all information available to the Company
concerning its condition, financial and otherwise, its management, its business
and its prospects. The Company represents that it has provided Consultant with a
copy of the Company's private placement memorandum dated February 27, 1998,
together with the Company's unaudited financial statements for the nine months
ended September 30, 1998. Consultant acknowledges that it is aware that because
of the Company's financial position, the nature of the Company's business and
products in development, the shares sold to Consultant as compensation hereunder
involve a high degree of risk. Consultant further represents that it and its
advisors have been afforded the opportunity to discuss the Company with the
Company's management and to ask such questions of them as it has deemed
necessary.

                                        2

<PAGE>

The Company represents that it has provided and will continue to provide
Consultant with any information or documentation necessary to verify
the accuracy of the information contained in the documents described in this
Section 6.

         7. Assignment. This Agreement may not be assigned by either party
hereto without the written consent of the other but shall be binding upon the
successors of the parties; provided, however, that Consultant shall have the
right to sell or assign the shares sold hereby in accordance with prevailing
securities laws.

         8. Arbitration. Any dispute arising between the Company and Consultant
arising out of or related to this Agreement or breach thereof shall be settled
by arbitration, which shall be conducted in Las Vegas, Nevada. Any award made by
such arbitrators shall be binding and conclusive for all purpose thereof, may
include injunctive relief as well as orders for specific performance, and may be
entered as a final judgment in any court of competent jurisdiction. No
arbitration arising out of or relating to this Agreement shall include, by
consolidation or joinder or in any other manner, parties other than the Company
or Consultant and other persons substantially involved in common questions of
fact or law whose presence is required if complete relief is to be afforded in
arbitration. The cost and expenses of such arbitration shall be borne in
accordance with the determination of the arbitrators and may include reasonable
attorney's fees. Each party hereby further agrees that service of process may be
made upon it by registered or certified mail or personal service at the address
provided for herein.

         9. Notices. All notices required or permitted to be given under this
Agreement shall be in writing and shall be deemed to have been duly given: (i)
when delivered personally to the party to be notified; or (ii) three (3)
business days after deposited in the U.S. or Canadian mail, postage paid via
registered or certified mail, return receipt requested. Notices to the Company
shall be addressed to its president at its principal executive office and to the
Consultant at the address set forth beneath the signature line, or to such other
addresses as either party may designate upon at least ten days' notice to the
other party.

         10. Governing Law. This Agreement shall be construed by and enforced in
accordance with the laws of the State of Nevada.

         11. Entire Agreement. This Agreement contains the entire understanding
and agreement between the parties. There are no other agreements, conditions or
representations, oral or written, express or implied, with regard thereto. This
Agreement may be amended only in writing signed by both parties.

                                        3

<PAGE>

         12. Non-Waiver. A delay or failure by either party to exercise a right
under this Agreement, or a partial or single exercise of that right, shall not
constitute a waiver of that or any other right.

         13. Headings. Headings in this Agreement are for convenience only and
shall not be used to interpret or construe its provisions.

         14. Counterparts. This Agreement may be executed in counterparts, each
of which shall be deemed an original but all of which together shall constitute
one and the same agreement.

         15. Binding Effect. The provisions of this Agreement shall be binding
upon the parties, their successors and assigns.

         16. Severability. If any provisions of this Agreement except paragraphs
1 and 3, or application thereof to any person or circumstance, shall be deemed
or held to be invalid, illegal or unenforceable to any extent, the remainder of
this Agreement shall not be affected and the application of such affected
provision shall be enforced to the greatest extent possible under law.

          IN WITNESS WHEREOF, the parties hereto have executed and delivered
this Agreement be effective as of the day and year first above written.

ATTEST:                               STEROIDOGENESIS INHIBITORS
                                      INTERNATIONAL, a Nevada
                                      Corporation

______________________________        By:____________________________________
                                              Alfred T. Sapse, President

ATTEST:                               THE AUGUSTINE EQUITY FUND

______________________________        By:____________________________________
                                                              (Title)

                                        4<PAGE>

                                    AGREEMENT

         THIS AGREEMENT is made and entered into this 5th day of March, 1999, by
and between AIDS RESEARCH Alliance (ALLIANCE), a California nonprofit public
benefit corporation having an office at 621A North San Vicente Boulevard, West
Hollywood, California 90069, and Steroidogenesis Inhibitors International
Corporation (SII), a Nevada corporation having an office at 2001 E. Flamingo
Road, Suite 100-B, Las Vegas. NV 89119.

I. Purpose

         This agreement is intended to enable Alliance and SII to obtain an
initial evaluation, through a trial to be conducted by Alliance in accordance
with a protocol that has been approved by both parties, of the positive and
negative effects on human subjects of an experimental drug developed by SII and
known as Anticort. SII will provide sufficient quantities of Anticort for the
trial. Alliance will conduct and compile the results of the trial in accordance
with this agreement and the protocol.

II. Anticort Trial Protocol

         The Anticort trial shall be conducted in accordance with this agreement
and the protocol (the Protocol) approved by both Alliance and SII attached as
Exhibit A hereto. No modification, revision or amendment to the Protocol shall
be valid or effective for any purpose unless in writing and duly executed by
both Alliance and SII in the same manner as the Protocol attached as Exhibit A
hereto.

III. Delivery of Anticort

         Throughout the course of the trial, SII shall deliver to Alliance such
quantities of Anticort as are, in the judgment of Alliance, sufficient to enable
Alliance to conduct the trial in accordance with the Protocol. All Anticort
delivered to Alliance shall have been manufactured, finished and filled in
accordance with the Good Manufacturing Practice regulations promulgated by the
United States Food and Drug Administration in Title 21 of the Code of Federal
Regulations, and packaged in a condition that permits consumption by humans in
accordance with all applicable laws and regulations of the State of California.

IV. Implementation of the Protocol

    (a) Upon receipt of Anticort from SII in accordance with Section III
        Alliance shall, subject to sections IV and XI, make all reasonable
        efforts to implement the Protocol.

<PAGE>

        SII shall consult and cooperate with Alliance on all aspects of and at
        all times during the course of the Anticort trial.

    (b) SII shall be responsible for payment of the costs of conducting the
        Anticort trial in accordance with this section IV and section XI.
        Alliance and SII agree that, based on the best information available to
        each of them as of the execution of this agreement, the total costs of
        the Anticort trial are, unless adjusted or revised in accordance with
        paragraph (c) of this section IV, not expected to exceed the amount
        shown on the budget attached as Exhibit B to this agreement. SII shall,
        upon execution of this agreement, pay to Alliance the sum of
        $226,885.75, representing an initial installment payment of thirty-five
        percent (35%) of the total costs projected in the attached budget. The
        balance of the budget amount shall be placed in an escrow account at the
        bank of Alliance's direction. Interest earned while the funds are in the
        escrow account shall accrue to the benefit of SII. Funds may be
        withdrawn from the escrow account by Alliance in the amount equal to the
        percentage of such costs, as adjusted or revised pursuant to paragraph
        (c) of this section IV upon reaching the milestones indicated in the
        following table:
<TABLE>
<CAPTION>

                                                 Amount (unless
Installment            % of Total              budget amended per
  Number                 Budget                    section IV)                    Due Upon
--------------------------------------------------------------------------------------------------
<S>                     <C>                      <C>                     <C>
                                                                         Enrollment of the first
     2                     5%                      $32,412.25            cohort of patients (the
                                                                         first dose level of the
                                                                         study - per the protocol)
--------------------------------------------------------------------------------------------------
                                                                         Completion of Week 4
     3                     5%                      $32,412.25            (Day 21) of the first
                                                                         cohort.
--------------------------------------------------------------------------------------------------
                                                                         Enrollment of the second
     4                     5%                      $32,412.25            cohort of patients (the
                                                                         second dose level of the
                                                                         study - per the protocol)
--------------------------------------------------------------------------------------------------
                                                                         Completion of Week 4
     5                     5%                      $32,412.25            (Day 21) of the second
                                                                         cohort.
--------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------
<S>                     <C>                      <C>                     <C>
                                                                         Enrollment of the third
     6                     5%                      $32,412.25            cohort of patients (the
                                                                         third dose level of the
                                                                         study - per the protocol)
--------------------------------------------------------------------------------------------------
                                                                         Completion of Week 4
     7                     5%                      $32,412.25            (Day 211) of the third
                                                                         cohort.
--------------------------------------------------------------------------------------------------
                                                                         Enrollment of the fourth
     8                     5%                      $32,412.25            cohort of patients (the
                                                                         fourth dose level of the
                                                                         study - per the protocol)
--------------------------------------------------------------------------------------------------
                                                                         Completion of Week 4
     9                     5%                      $32,412.25            (Day 21) of the fourth
                                                                         cohort.
--------------------------------------------------------------------------------------------------
                                                                         Completion of Week 11
    10                     10%                     $64,824.5             (Day 70) of all patients
                                                                         in all four cohorts.
--------------------------------------------------------------------------------------------------
                                                                         Delivery of all study data
 11 (final)                10%                     $64,824.5             and the study report, as
                                                                         provided for in the
                                                                         Protocol.
--------------------------------------------------------------------------------------------------
</TABLE>

           (c)  The amount of costs projected in the budget may be adjusted or
                revised at such times and in such amounts as may be agreed upon
                by Alliance and SII in connection with any modification,
                revision or amendment to the Protocol. Study participants who
                drop out of the study prior to completion will be replaced with
                additional participants. Such replacements, if there are any,
                shall increase the budget accordingly. Alliance shall be paid on
                a pro-rata basis for any participants who drop out of the study,
                pursuant to the visit-based, line-item budget. Any augmentations
                to the budget necessitated by the replacement of drop-outs shall
                be paid in the 10th installment, prior to the final delivery of
                the study data and study report.

           (d)  SII may rely on the clinical study monitor hired by SII to
                monitor this study to verify that budget milestones have been
                reached.

<PAGE>

V. Representations and Warranties By SII

         SII hereby represents and warrants to Alliance that it has clear and
unencumbered legal right and title to the use of Anticort, and that the delivery
to Alliance of Anticort and the use of Anticort pursuant to this agreement does
not and will not constitute a breach, infringement or other invasion of the
rights of any other individual, corporation or other entity to own, license,
exploit, possess or use for any purpose Anticort or any other substance, product
or tangible thing which any third party may claim Anticort is derived from or is
in any way related to.

VI. Audits or Investigations

         For a period commencing with the execution of this agreement and
continuing through the end of the fifth anniversary of the date on which the
administration of Anticort to a human subject during the Anticort trial last
occurred, Alliance and SII each agree to notify the other within three business
days of the receipt of any inquiry from, or notice of an audit or investigation
of the Anticort trial by, any federal, state or local regulatory or enforcement
agency, and shall consult with each other prior to responding to any such
inquiry, audit or investigation.

VII. Ownership and Publication of Data, Results and Papers

         (a) Subject to paragraphs (b), (c) and (d) of this section VII, all
writings of any kind and description delivered by either party to the other
concerning Anticort, or containing data from or results of the Anticort trial,
shall be owned by the author thereof and shall not be disclosed or delivered to
any third party for any purpose, other than pursuant to an order from a court of
competent jurisdiction, without the express written consent of the owner.

         (b) Notwithstanding paragraph (a) of this section VII, Alliance or SII
may prepare formal research papers concerning the Anticort trial on a joint or
independent basis provided, however, (i) that each party shall provide due
credit for and acknowledgment of the role played by the other in the design and
implementation of the Anticort trial, (ii) that each party preparing a paper on
an independent basis shall provide the other with thirty (30) calendar days
notice in advance of the initial submission thereof, on a formal or informal
basis, to a publication, academic institution, professional society or other
organization and shall, upon request by written notice received at least three
(3) calendar days prior to the date for such initial submission, permanently
delete from the manuscript of such paper all reference to or credit for the
participation of the other party and (iii) upon request by written notice from
SII to Alliance of an intent to file a patent application for or in any way
relating to Anticort. Alliance shall delay the initial submission of any paper
for a period of ninety (90) days from receipt of such notice.

<PAGE>

         (c) Notwithstanding paragraph (a) of this section VII, each party may,
upon the express written consent of the other party, disclose the existence of
the Anticort trial and the participation of the other party therein through one
or more communications to third parties.

         (d) Notwithstanding paragraph (a) of this section VII, Alliance
expressly acknowledges and agrees that any and all patents, patent applications,
intellectual property and any and all inventions, discoveries, indications,
treatments, improvements, new technologies or other developments, whether
patentable or unpatentable and regardless of whether copyrightable (the
"Discoveries"), resulting from or arising out of the Anticort trial shall at all
times be and remain the sole and exclusive property of SII, and that Alliance
and its employees or agents shall execute and deliver to SII all instruments
required to confirm, convey or assign exclusive ownership of the Discoveries in
or to SII. SII hereby grants to Alliance a royalty-free nonexclusive right to
use the Discoveries in the course of the Anticort trial and in any research
undertaken by Alliance in the future on a nonprofit basis, and to publish its
findings with respect thereto in accordance with paragraph (b) of this
section VII.

VIII. Indemnification

         SII and Alliance shall each indemnify, defend and save harmless the
other, and the directors, officers, employees and agents thereof, from and
against any and all liability, losses, damages errors and omissions and/or
expense arising from or relating to the Anticort trial, including, but not
limited to, defense costs and legal fees, as follows:

         (a) SII shall indemnify Alliance from and against all claims for
damages for personal injury arising from, resulting or allegedly resulting from
the Anticort trial including, without limitation, bodily injury, emotional
distress, death, or other personal injury of any kind or description provided
that such personal injury is not attributable to the negligence or wrongful act
of Alliance or its agents and employees. Negligence or wrongful act shall
include the conduct of research contrary to the Protocol in one or more material
respects.

         (b) Alliance shall indemnify SII from and against all claims for
damages for personal injury arising from, resulting or allegedly resulting from
the Anticort trial attributable to the negligence or wrongful act of Alliance
or its agents and employees including, without limitation, bodily injury,
emotional distress, death, or other personal injury of any kind or description.
Negligence or wrongful act shall include the conduct of research contrary to the
Protocol in one or more material respects.

         (c) SII shall indemnify Alliance from and against all claims by third
parties for damages for or injunction against property damage arising from,
resulting or allegedly resulting from the Anticort trial including, without
limitation, any past, present or future damage to any property belonging to or
in the care, custody or control of Alliance, SII or any third party, including
physical damage

<PAGE>

to or loss of real property or tangible personal property, or any past, present
or future damage to or impairment of intangible property, including intellectual
property protected or allegedly protected by patent, patent pending, trademark,
copyright or common law or any claim of right under a patent, patent pending,
trademark, copyright or common law.

         (d) SII shall indemnify Alliance from and against all claims or
expenses in or arising from any civil or criminal proceeding or inquiry brought
or commenced by any governmental agency arising from or relating to the Anticort
trial, unless such claims or proceedings arise from or are attributable to the
negligence or wrongful act of Alliance or its agents or employees. Negligence or
wrongful act shall include the conduct of research contrary to the Protocol in
one or more material respects.

IX. Disclaimer of Alliance Liability

         SII agrees that Alliance, and the directors, officers, employees or
agents of Alliance, shall not be liable to and owe no duty to SII for any losses
incurred by SII and the directors, officers, employees or agents of SII
resulting from or incurred under this agreement including, without limitation,
bodily injury, death, personal injury, or any past, present or future damage to
any property, including physical damage to or loss of property belonging to SII
while such property is in the care, custody or control of Alliance, or any past,
present or future damage to or impairment of intangible property, including
intellectual property protected or allegedly protected by patent, patent
pending, trademark, copyright or common law or any claim of right under a
patent, patent pending, trademark, copyright or common law.

X. Insurance

         Alliance and SII each hereby represent and warrant to the other that it
currently maintains comprehensive general liability insurance, including errors
and omissions or professional malpractice liability insurance, in the amounts of
not less than $1,000,000 per occurrence and $2,000,000 aggregate. Without
limiting the indemnification obligations of each party pursuant to section VIII,
or the disclaimer of Alliance liability pursuant to section IX, each of Alliance
and SII shall, for a period of two years commencing with the execution of this
agreement, (i) maintain insurance coverage at or above the current occurrence
and aggregate limits of the policies specified in the first sentence of this
section IX and (ii) obtain endorsements naming the other as an additional
insured under each such policy.

XI. Termination

         Either Alliance or SII may, at any time, advise the other by written
notice that implementation or completion of the Protocol, or performance of this
agreement, has become

<PAGE>

impossible due to circumstances beyond the control of the party giving such
notice. This agreement and the Anticort trial shall terminate thirty (30)
calendar days following such notice. In the event of termination pursuant to
this section XI, the obligations of Alliance shall be limited to (i) returning
to SII all Anticort then currently in the possession of Alliance, (ii) executing
and delivering to SII all instruments required to effect compliance by Alliance
with its obligations pursuant to paragraph (d) of section VII and (iii)
providing SII with copies of all papers, tapes, disks, diskettes or other
tangible materials currently in its possession that would have been provided to,
or would have become the basis for other papers to be provided to, SII pursuant
to section VII of this agreement and the Protocol provided, however, that
Alliance shall have no obligation to create or in any way edit any papers,
tapes, disks, diskettes or other tangible documents, writings or other
materials. In the event of termination pursuant to this section XI, Alliance
shall be entitled to payment for, and SII shall pay within ten (10) business
days of receipt of an invoice therefor, all direct and indirect costs actually
incurred by Alliance in connection with the Anticort trial which, as of the date
of termination, remain unreimbursed through one or more of the installments
already paid by SII pursuant to section IV. Alliance and SII expressly agree and
acknowledge that, notwithstanding the termination of this agreement pursuant to
this section XI, the provisions of sections VI, VIII, X and XI shall survive and
remain in effect in accordance with their respective terms.

XII. Use of Parties Names

         Alliance and SII will obtain prior written permission from each other
before using the name, symbols and/or trademarks of the other party in any form
of publicity. This shall not include legally required disclosure by Alliance or
SIT that identifies the existence of this Agreement.

XIII. Waivers

         No waiver by either party of a breach of any provision of this
agreement shall constitute a waiver of any other breach of such provision.
Failure of either party to enforce at any time, or from time to time, any
provision of this agreement shall not be construed as a waiver thereof.

XIV. Entire Agreement and Construction With Protocol

         This agreement shall constitute the complete and exclusive statement of
the understanding of the parties concerning their respective rights and
obligations arising from, relating to or concerning the Anticort trial. In the
event of any conflict or inconsistency between this agreement and the Protocol,
the provisions of this agreement shall govern and shall be given conclusive
effect.

<PAGE>

XV. Modifications

         No modification, amendment, waiver or release of any provision of this
agreement or of any right, obligation, claim or cause of action arising
hereunder shall be valid or binding for any purpose unless in writing and duly
executed by both Alliance and SII in the same manner as this agreement.

XVI. Governing Law

         This agreement shall be governed by and construed in accordance with
the laws of the State of California.

XVII. Notices

         All notices by either party to the other hereunder, including notice of
a change in the address information set forth below, shall be in writing and
shall be delivered either by first class mail, postage prepaid, or by facsimile
transmission during regular weekday business hours which shall be effective only
upon receipt by the sender of confirmation by telephone of the date and time of
receipt thereof from a full time employee of the recipient, and shall be
addressed as follows:

          Alliance:    AIDS RESEARCH Alliance
                       Attention: Gregory Britt, CEO
                       621A North San Vicente Boulevard
                       West Hollywood, CA 90069
                       Fax: (310) 358-2431

          SII:         Steroidogenesis Inhibitors International Corporation
                       Attention: Alfred Sapse, M.D.
                       President
                       2001 Flamingo Road, Suite 100-B
                       Las Vegas, NV 89119
                       Fax: (702) 733-9505

<PAGE>

         IN WITNESS WHEREOF, each of Alliance and SII have caused this agreement
to be subscribed in its behalf by its duly authorized officer on the day, month
and year first above written.

          AIDS RESEARCH ALLIANCE                    SII CORPORATION

          By /s/ Gregory S. Britt                   By /s/ Alfred Sapse, M.D.
             ---------------------                     -----------------------
             Gregory S. Britt                          Alfred Sapse, M.D.
             Chief Executive Officer                   President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}]]